VEGFA and neoplasm: Inhibitors of VEGF, such as bevacizumab [108], and small-molecule tyrosine kinase inhibitors targeting VEGFR, such as sunitinib and sorafenib [109], have demonstrated efficacy in reducing tumor vascular density and delaying progression.